Prostaglandin E₂ Increases Lentiviral Vector Transduction Efficiency of Adult Human Hematopoietic Stem and Progenitor Cells

Garrett C. Heffner, Melissa Bonner, Lauryn Christiansen, Francis J. Piercicy, Dakota Campbell, Yegor Smurnyy, Wenliang Zhang, Amanda Hamel, Seema Shaw, Gretchen Lewis, Kendrick A. Goss, Olivia Garijo, Bruce E. Torbett, Holly Horton, Mitchell H. Finer, Philip D. Gregory, and Gabor Veres

Gene therapy currently in development for hemoglobinopathies utilizes ex vivo lentiviral transduction of CD34⁺ hematopoietic stem and progenitor cells (HSPCs). A small-molecule screen identified prostaglandin E₂ (PGE₂) as a positive mediator of lentiviral transduction of CD34⁺ cells. Supplementation with PGE₂ increased lentivector (LVV) transduction of CD34⁺ cells approximately 2-fold compared to control transduction methods with no effect on cell viability. Transduction efficiency was consistently increased in primary CD34⁺ cells from multiple normal human donors and from patients with β-thalassemia or sickle cell disease. Notably, PGE₂ increased transduction of repopulating human HSPCs in an immune-deficient (nonobese diabetic/severe combined immunodeficiency/interleukin-2 gamma receptor null [NSG]) xenotransplantation mouse model without evidence of in vivo toxicity, lineage bias, or a de novo bias of lentiviral integration sites. These data suggest that PGE₂ improves lentiviral transduction and increases vector copy number, therefore resulting in increased transgene expression. As a result, PGE₂ may be useful in clinical gene therapy applications using lentivirally modified HSPCs.

INTRODUCTION

Hematopoietic stem cell transplantation is a potentially curative therapy for multiple clinical indications. As the only long-term self-renewing cell of the hematopoietic system, long-term hematopoietic stem cells (LT-HSCs) are the optimal targets for gene therapy for patients with non-malignant disorders currently treated with allogeneic stem cell transplant. Early promising results with therapeutic applications of lentivector (LVV)-transduced hematopoietic stem cells (HSCs) have been achieved. Despite these early successes, it has been challenging to achieve robust and reliable genetic modification of HSCs for all patients and across a variety of therapeutic indications. Overcoming this challenge would expand the therapeutic potential of stem cell-based gene therapy, particularly in disorders where a high level of transgenic expression is required. HSC resistance to infection has been attributed to the quiescent (G₀) phase of the cell cycle of HSCs or to other innate immune defenses against viral transduction at the level of viral fusion and entry, including proteasomal activity. Consequently, approaches to improve lentiviral transduction of HSCs (CD34⁺ cells) have included soluble factors or gene modulation strategies intended to overcome transduction resistance, including modulation of p21 expression, modulation of mTOR activity, and relief of early capsid-dependent barriers to transduction. To date, no strategies for increasing LVV transduction efficiency had proven to be sufficiently robust to be brought into the clinic for gene therapy of hematopoietic disorders.

To identify novel clinically applicable small-molecule factors that could improve lentiviral transduction of CD34⁺ cells, we performed a high-throughput small-molecule screen on primary CD34⁺ cells from mobilized peripheral blood from healthy human donors. This screen identified prostaglandin E₂ (PGE₂) as a candidate vector copy number enhancer. We determined that PGE₂ increased the level of lentiviral transgene delivery in ex vivo culture for CD34⁺ cells derived from both healthy human donors and human donors with primary hemoglobinopathies. PGE₂ also increased gene delivery in nonobese diabetic/severe combined immunodeficiency/interleukin-2 gamma receptor null (NSG)-repopulating cells. Moreover, PGE₂ did not exhibit bias relative to the integration-site profile in CD34⁺ cells transduced in the absence of PGE₂. Cumulatively, these data support the potential use of PGE₂ to increase LVV transduction of HSCs for clinical gene therapy applications.

Received 22 November 2016; accepted 29 September 2017; https://doi.org/10.1016/j.ymthe.2017.09.025.
RESULTS
Small-Molecule Screen Identifies Candidate Soluble Factors to Improve Transduction of CD34+ Cells
In order to identify candidate molecules that could improve lentiviral transduction of CD34+ cells in an ex vivo culture protocol, we performed a small-molecule screen for improved transduction of CD34+ cells with a standard vesicular stomatitis virus G (VSVG)-pseudotyped GFP-containing LVV. To facilitate the potential for rapid implementation in a Good Manufacturing Practice process, we selected the ScreenWell US Food and Drug Administration (FDA)-approved Drug Library v2 (Enzo Life Sciences), which contained more than 780 compounds, including known antiretroviral compounds that could serve as negative controls and vehicle-only wells that would serve as no-supplement controls. We prestimulated mPB from a healthy human subject for 48 hr at 1 × 10^6 cells/mL in cytokine-supplemented media, followed by transduction with a GFP lentivirus at an MOI of 25 and a distribution of ~50,000 cells/well in a 96-well format. We then added compounds to a final concentration of 10 μM, each concurrent with lentiviral transduction, and washed after 24 hr of transduction. Cells were then cultured for an additional 72 hr in cytokine-supplemented media, and volumetric flow cytometry analysis was performed to simultaneously measure cell yield and GFP positivity for all 780 compounds.

As depicted in Figure 1A, under these conditions the majority of compounds supported transduction levels of approximately 20% GFP+, which was indistinguishable from the untreated controls. Consistent with their anticipated role in decreasing lentiviral transduction, known antiretroviral compounds such as efavirenz (1.19%), emtricitabine (0.49%), and zalcitabine (0.06%) yielded significantly decreased levels of GFP+ cells in this assay. This screen also identified a number of compounds that drove significantly greater levels of transduction in conjunction with favorable cell yields. These compounds included everolimus (mTOR modulation; 54.9% GFP+), vorinostat (histone deacetylase [HDAC] inhibition; 54.2%), nebivolol (β1 receptor blocker; 50.9%), paroxetine (selective serotonin reuptake inhibitor; 45.8%), mefloquine (anti-malarial; 43.2%), amiodipine (calcium channel blocker; 38.1%), and dinoprostone (bioactive lipid, hereafter referred to as PGE2; 29.5%). Importantly, identification of everolimus and vorinostat is supported by previous publications, which

Figure 1. PGE₂ Enhances Transduction of CD34+ Cells with LVV
(A) The results of a 780-compound small-molecule screen are depicted. Each compound is represented as a data point with the percentage of GFP+ cells indicated on the x axis and the volumetric recovery of cells, on a log scale, indicated on the y axis. Blue dots denote compounds selected for follow-up analysis. (B and C) In a follow-up experiment with 10, 3.3, or 1 μM of seven candidate compounds, the percentage of GFP+ cells (B) and the volumetric recovery of cells (C) are indicated for triplicate wells per compound per concentration of compound, as assessed at day 7 post-transduction. (D) Transduction of CD34+ cells with BB305 LVV supplemented with 10 μM candidate compound as indicated; the mean VCN is indicated for triplicate wells per compound, as assessed at day 7 post-transduction. (E) Mean VCN from CD34+ cells derived from 16 unique healthy donor cell lots, transduced with BB305 LVV supplemented with 10 μM PGE2 during the transduction step, as assessed at day 7 post-transduction. Pairwise comparisons of VCN for each cell lot, in the presence or absence of PGE2, are indicated by a line. LVV, lentiviral vector; PGE2, prostaglandin E2; VCN, vector copy number.
also identified mTOR inhibition as a modulator of lentiviral transduction.\textsuperscript{10,11,13,14}

Based on this primary screen, we selected seven compounds for further analysis. Specifically, we performed an additional transduction of CD34\(^+\) cells with GFP LVV in the presence of each molecule using a small concentration titration (10, 3, or 1 \mu M). As illustrated in Figures 1B and 1C, paroxetine, nebivolol, amlodipine, meloquine, and PGE\(_2\) yielded elevated GFP\(^+\) cells relative to vehicle in a concentration-dependent manner, with cell yield equivalent to that of vehicle. By contrast, we were unable to observe cell yield equivalent to that of vehicle in our analysis of everolimus or vorinostat at the tested concentrations, and we therefore eliminated these compounds from further study.

**PGE\(_2\) Promotes Transduction of CD34\(^+\) Cells with a Globin-Containing LVV**

We then further test our lead compounds in a preclinical model of LVV-mediated gene therapy for severe hemoglobinopathies. We transduced mPB-derived CD34\(^+\) cells from healthy human donors using a recombinant LVV encoding the human \(\beta\)-globin gene at an MOI of 25 in the presence or absence of 10 \mu M of each candidate compound. As illustrated in Figure 1D, we observed the greatest increase in vector copy number (VCN) with 10 \mu M PGE\(_2\). Based on these results, we selected PGE\(_2\) for further study.

To assess the robustness of the transduction enhancement effect of PGE\(_2\), we transduced mPB CD34\(^+\) cells from 16 healthy donors with recombinant LVV encoding the human \(\beta\)-globin gene in the presence or absence of 10 \mu M PGE\(_2\). As illustrated in Figure 1E, PGE\(_2\) resulted in improved transduction across 16 lots of CD34\(^+\) cells from healthy donors, with VCN increasing by an average of 1.9-fold for each donor sample (0 \mu M PGE\(_2\): mean VCN 2.14 ± 0.62, range 1.28–3.12; 10 \mu M PGE\(_2\): mean VCN 4.08 ± 0.93, range 2.72–5.51). Based on these observations, we conclude that exposure to 10 \mu M PGE\(_2\) during LVV transduction of CD34\(^+\) cells results in an approximately 2-fold increase in gene marking of CD34\(^+\) HSCs from healthy donors.

To assess the ability of PGE\(_2\) to increase the effective transduction of CD34\(^+\) cells over a broader range of MOI, we transduced CD34\(^+\) cells at MOIs of 4, 8, 12, 16, and 32 in the presence or absence of 10 \mu M PGE\(_2\). As illustrated in Figure S1, although we saw a relative “plateau” of transduction at higher MOI in unsupplemented samples, we observed a progressive increase in VCN when increasing MOI in the presence of 10 \mu M PGE\(_2\). VCNs achieved upon supplementation with PGE\(_2\) were, in all cases, elevated relative to CD34\(^+\) cells transduced in the absence of PGE\(_2\). We thus conclude that supplementation with PGE\(_2\) is sufficient to increase transduction levels beyond the range that can be expected to be achieved through modulation of MOI alone.

Finally, to further support the safety profile of exposure to 10 \mu M PGE\(_2\) during LVV transduction, we assessed the viability and cell counts of CD34\(^+\) cells cultured in the presence or absence of 10 \mu M PGE\(_2\) during LVV exposure, and compared these results to cells cultured in the absence of LVV. As illustrated in Figure S2, we did not see evidence of toxicity or diminished cell yields associated with PGE\(_2\) exposure. Thus, based on our aggregate experience with in vitro assays, we conclude that supplementation with 10 \mu M PGE\(_2\) during LVV transduction is associated with a favorable safety and efficacy profile, supporting subsequent in vivo studies.

**PGE\(_2\) Does Not Promote Viral Entry**

To determine at which step in the LVV transduction cycle PGE\(_2\) exerts an effect, we performed a \(\beta\)-lactamase (BlaM) assay using VPR-BlaM-loaded LVV particles that readout viral entry versus later stage of the LVV integration process.\textsuperscript{15} We did not observe an increase in BlaM\(^+\) cells when CD34\(^+\) cells were transduced with this LVV in the presence of 10 \mu M PGE\(_2\) as compared to cells transduced in the presence of vehicle control (Figure S3). This suggests that PGE\(_2\) does not exert its transduction enhancement effects via elevated levels of viral entry during LVV transduction of CD34\(^+\) cells.

**PGE\(_2\) Exposure during Ex Vivo Transduction Is Associated with Comparable Human CD45\(^+\) Engraftment and Elevated VCN in NSG Xenotransplant**

To address the ability of PGE\(_2\) to mediate enhanced gene transfer to a population of cells enriched for LT-HSCs, we first tested the transduction of a prospectively identified primitive CD34\(^+\) CD38\(^-\) cell population sorted from mPB from healthy human donors in the presence or absence of 10 \mu M PGE\(_2\). As indicated in Figure S4, 10 \mu M PGE\(_2\) resulted in elevated VCN in CD34\(^+\) CD38\(^-\) cells (0 \mu M PGE\(_2\): mean 0.65 ± 0.23 SD; 10 \mu M PGE\(_2\): mean 2.12 ± 0.16 SD). This increase was comparable to the VCN elevation noted in a parallel culture of bulk CD34\(^+\) cells (0 \mu M PGE\(_2\): mean 1.02 ± 0.25 SD; 10 \mu M PGE\(_2\): mean 2.65 ± 0.67 SD). These results indicate that adding PGE\(_2\) during transduction can increase VCN in a population of CD34\(^+\) cells enriched for potential LT-HSC activity. To demonstrate improved gene transfer to the HSC compartment in a xenotransplant setting, we performed a transplant of bulk CD34\(^+\) cells transduced with LVV in the presence or absence of PGE\(_2\) into the NSG mouse model. CD34\(^+\) cells from mPB of four healthy human donors were transduced with a GFP LVV and 1 million cells transplanted per mouse (15–25 mice per group). For each mouse, we assessed the level of human (hu) CD3 (huCD3), huCD19, huCD33, and huCD45 chimerism, GFP\(^+\) cells within huCD45\(^+\) cells, and VCN from bone marrow at 4 months post-transplant. As illustrated in Figure 2A, we did not observe a difference in huCD45 chimerism in bone marrow between vehicle-treated CD34\(^+\) cells and PGE\(_2\)-treated CD34\(^+\) cells assessed 4 months after transplant. We did not observe a difference in the differentiation potential of these cells based on the analysis of CD3, CD19, or CD33 staining in the bone marrow (Figures 2B–2D). We observed a net increase in VCN in the bone marrow of engrafted mice at 4 months post-transplant (VCN vehicle = 0.84; VCN PGE\(_2\) = 1.3; \(p = 0.001\); Figure 2E; Table 1). Transplants with three of four donors resulted in a significant increase in VCN at this time point. In addition to these data with GFP-containing...
LVV, we subsequently demonstrated the ability of PGE2 to mediate elevated levels of VCN 4 months after transplant in a xenotransplant setting using an optimized beta-globin-containing LVV (data not shown; unpublished data). In addition, we observed no lineage skewing due to vehicle exposure relative to mock exposure (Figure S5).

Together, these data demonstrate that transplant of CD34+ cells transduced with LVV generally results in increased in vivo VCN 4 months after transplant in a humanized mouse model.

Absence of Integration-Site Bias Associated with PGE2-Enhanced LVV Transduction of CD34+ Cells

To determine whether PGE2 modulated the integration-site profile during lentiviral transduction, we performed linear amplification-mediated PCR (LAM-PCR) on post-transplant samples isolated from 4-month bone marrow from 80 engrafted NSG mice, of which 40 had received CD34+ cells transduced with a GFP-containing LVV in the presence of 10 μM PGE2 and 40 had received CD34+ cells transduced in the presence of 0.1% DMSO vehicle control. We first quantified the distribution of integration sites in relation to transcriptional start sites and intragenic regions, as well as downstream of transcriptional stop sites. We observed no difference between PGE2-exposed or vehicle-exposed samples in the distribution patterns of integration sites in the genomic regions up to 30 kb upstream or downstream of transcriptional start or termination sites, or in the distribution of integration sites normalized to position within a transcriptional region (Figure 3A). We assessed the integration-site profiles in a broader context in the genome, to assess the distribution patterns in locations adjacent to transcriptionally active loci, within exons, within intergenic regions, within introns, or within untranslated regions of genes. We did not identify differences between PGE2- or vehicle-exposed samples in these distribution patterns (Figure 3B). We then identified the most frequent integration sites in each of 80 transplanted mice, and mapped each integration site to a 1-Mb region of the genome. We found no differences between the distribution of the number of insertion sites per megabase in vehicle-treated and PGE2-treated cells (Figure 3C). Exposure of CD34+ cells to PGE2 during LVV transduction was not associated with LVV integration-site bias in 4-month NSG-engrafting LVV-transduced human CD34+ cells.

Finally, we addressed the possibility that supplementation with PGE2 could influence LVV integration with respect to sites adjacent to known oncogenes or tumor suppressor genes. The lists of tumor suppressor and oncogenes were obtained from UniProt database (PMID 25348405). After completion of integration-site analysis for each engrafted mouse, we annotated each insertion site as being within 30 kb from 4-month bone marrow from 80 engrafted NSG mice, of which 40 had received CD34+ cells transduced with a GFP-containing LVV in the presence of 10 μM PGE2 and 40 had received CD34+ cells transduced in the presence of 0.1% DMSO vehicle control. We first quantified the distribution of integration sites in relation to transcriptional start sites and intragenic regions, as well as downstream of transcriptional stop sites. We observed no difference between PGE2-exposed or vehicle-exposed samples in the distribution patterns of integration sites in the genomic regions up to 30 kb upstream or downstream of transcriptional start or termination sites, or in the distribution of integration sites normalized to position within a transcriptional region (Figure 3A). We assessed the integration-site profiles in a broader context in the genome, to assess the distribution patterns in locations adjacent to transcriptionally active loci, within exons, within intergenic regions, within introns, or within untranslated regions of genes. We did not identify differences between PGE2- or vehicle-exposed samples in these distribution patterns (Figure 3B). We then identified the most frequent integration sites in each of 80 transplanted mice, and mapped each integration site to a 1-Mb region of the genome. We found no differences between the distribution of the number of insertion sites per megabase in vehicle-treated and PGE2-treated cells (Figure 3C). Exposure of CD34+ cells to PGE2 during LVV transduction was not associated with LVV integration-site bias in 4-month NSG-engrafting LVV-transduced human CD34+ cells.
of either oncogene, tumor suppressor, or neither. We calculated the percentages of reads found in tumor suppressor and oncogene loci for each animal and used one-way ANOVA to test for statistical significance between DMSO- and PGE2-treated animals. Our data are summarized in Table S1. Interestingly, although we observed a trend toward fewer integration sites adjacent to known oncogene and tumor suppressor genes upon supplementation with PGE2 during the transduction process, the trends did not achieve statistical significance (p values were p = 0.87 for oncogenes and p = 0.16 for tumor suppressors). Thus, PGE2 does not impact distribution of insertion sites among tumor suppressor or oncogenes. Cumulatively, these analyses demonstrate that PGE2 supplementation during LV transduction is associated with a favorable integration-site safety profile relative to standard LV transduction processes.

**PGE2 Improves In Vitro Transduction of CD34+ Cells from People with β-Thalassemia and Sickle Cell Disease**

We investigated whether PGE2 could promote lentivirally mediated transduction, and increase transgenic hemoglobin protein expression, in primary CD34+ cells derived from patients with hemoglobinopathies. CD34+ cells from the mPB of a patient with transfusion-dependent β-thalassemia and CD34+ cells from the bone marrow of a patient with sickle cell disease were transduced with recombinant LVV encoding the human β-globin gene in the presence or absence of PGE2. Following transduction, cells were plated in methylcellulose to assess colony-forming unit potential. We observed an increase in the VCN of pooled colonies transduced in the presence of PGE2 relative to vehicle (Figure 4A). Surprisingly, we observed that the VCN in the absence of PGE2 at an MOI of 50, suggesting that PGE2 can increase LVV transduction of CD34+ cells above any increase in VCN from simple increase of the vector MOI used during transduction.

We then performed single-colony analysis of methylcellulose cultures to determine the frequency of transduced myeloid progenitors, as well as the number of integrations per cell. We observed an increase in the total number of vector-containing colonies (a measure of the percentage transduced), as well as an increase in the number of colonies with higher numbers of integration events per cell in both sickle cell disease and thalassemia cells transduced in the presence of 10 μM PGE2 relative to control (Figure 4B; Table 2). Finally, we isolated individual and pooled burst-forming unit-erythroid (BFU-E) colonies to perform high-performance liquid chromatography (HPLC) analysis of hemoglobin chains in these cells. We observed elevated levels of vector-derived β-globin in BFU-E derived from CD34+ cells transduced with LVV in the presence of 10 μM PGE2 in the context of both sickle cell disease and thalassemia CD34+ cells (Figures 4C–4G). These data demonstrate that PGE2 can promote lentiviral transduction and increase in therapeutic gene expression in primary CD34+ cells derived from patients with hemoglobinopathies.

**DISCUSSION**

An ongoing challenge to the promise of broad LVV-based gene therapy for hematopoietic indications has been to ensure robust and reliable genetic modification of HSCs. An optimal strategy for clinical application of virally mediated HSC gene transfer would permit delivery of sufficient therapeutic transgene into HSCs, while minimizing potentially adverse integration-site preference of vector in the host genome. Here, we have demonstrated that the addition of PGE2 improves lentiviral transduction of human hematopoietic stem and progenitor cells, without evidence of overt integration-site bias in lentivirally transduced cells. We anticipate that PGE2 will help low-transducing hematopoietic stem and progenitor cells to achieve better transduction and increase the likelihood of clinical benefit for a broader spectrum of patients. In the context of gene dosing in hemoglobinopathies, and additional indications where gene therapy may require stoichiometric elevations in the level of transgene delivery, improvements in the absolute VCN, mediated by PGE2, could be the critical difference ensuring a robust and successful treatment. In addition, even for indications where LVV transduction may already appear sufficient for clinical benefit, the incorporation of PGE2 may allow for elevated transduction with less vector and/or reduce patient-to-patient variability in achieving a threshold of transduction. Thus, although our analysis has largely focused on gene therapy for hemoglobinopathies, we anticipate that PGE2 could find relevance in many further applications for gene modification in CD34+ cells beyond these indications.

PGE2 and its chemical relative 16, 16-dimethyl PGE2 (dmPGE2) have been previously noted to have beneficial effects in promoting self-renewal and transduction efficacy in hematopoietic stem and progenitor cells (HSPCs).16,17 However, the relevance of a salutary effect on HSPC renewal to the goal of increasing viral transduction of HSPCs is not known; in fact, additional candidate HSPC self-renewal factors such as SR1, Wnt3a, SHH, and UM171 were not observed to improve LVV transduction in our hands (data not shown).18–21

Although the full mechanism is still under investigation, our data suggest a role of PGE2 that may be unique among the published clinical and preclinical efforts to use PGE2 to imbue improved clinical characteristics on CD34+ cells. Previous investigators have used...
short pulses of PGE2 to improve the transplantability of cord-blood-derived CD34+ cells, or long exposures of PGE2 in an attempt to better preserve stem and early progenitor cells during zinc-finger nuclease-mediated cleavage and homology-directed repair with integration-deficient LVV donor template.22,23 Because we have not seen transduction enhancement with short pulses (1–2 hr) of PGE2 (data not shown) and we observe no effect of PGE2 on CD34+ cell viability or cell number, we hypothesize that PGE2 can exert different mechanisms on CD34+ cells depending on the timing or context of exposure.

Interestingly, the marked transduction enhancement effect in vitro was somewhat muted in the transplant setting, potentially because of the general difficulty of transduction of the LT-HSC compartment.

Future studies of the involvement of PGE2 in modulating LVV transduction may address potential variability within the HSPC compartment for responsiveness to PGE2, for example, through assessment of variable modulation of viral restriction factors among these cell populations, or an assessment of patient-to-patient variability at the HSC level. Although such studies are beyond the scope of this paper, they may further illuminate the challenges in modulating LVV transduction in clinically relevant cell populations.

To our knowledge, we were the first to report that PGE2 increases LVV transduction of CD34+ cells (Heffner, et al., 2013, Mol Ther., abstract). Indeed, our results are unexpected given that PGE2 has been shown to decrease transduction of macrophage lineage cells.24,25 Although König et al.24 observed that disruption of a prostaglandin...
synthase, PTGES3, resulted in a diminished level of nuclear import of HIV preintegration complex, Gomez et al.27 and Malki et al.28 have reported an increased level of nuclear import of protein products in response to PGE2 or D2 signaling. Future work will address the specific mechanisms whereby PGE2 improves LVV transduction of CD34+ cells.

MATERIALS AND METHODS

Cell Culture

Research-grade GFP-, globin-, and ALDP-containing LVVs were produced at bluebird bio (Cambridge, MA, USA). CD34+ cells were cultured in CellGro stem cell growth media (SCGM; CellGenix, Freiburg, Germany), supplemented with recombinant human cytokines thrombopoietin, FltL, and stem cell factor at 100 ng/mL (CellGenix).

HPLC

HPLC analyses were performed with a Prominence chromatograph (Shimadzu, Somerset, NJ, USA) and its LC Solution software. Globin chains from pooled erythroid colonies were separated by
reverse-phase HPLC using a 4.6-mm Aeris 3.6-μM Widepore C4 Column (Phenomenex, Torrance, CA, USA). Samples were eluted with a gradient mixture of solution A (water with 0.1% trifluoroacetic acid) and solution B (acetonitrile with 0.08% trifluoroacetic acid). The absorbance was measured at 220 nm.

**PCR and VCN Assay**

Genomic DNA was isolated from cell cultures using QIAGEN DNeasy protocol (QIAGEN, Hilden, Germany). PCR was performed using TaqMan Fast Master Mix (Invitrogen, Carlsbad, CA, USA) and 0.9 μM GAG forward (5'-GAGGTAGACAAGCTGGTAGTTA-3') and reverse (5'-GGTTGATCCCCATGTGTTGC'TC) primers and GAG FAM probe [5'-(FAM)-ACACGCTTCGATGTCTC TAAAGGGCCAGG-(TAMRA)-3'] and RNASE-P-VIC control TaqMan assay (Invitrogen), and run using Fast program on Applied Biosystems StepOnePlus real-time thermocycler (Invitrogen). VCN was assessed relative to the Clone K3 cDNA, known to contain two copies of integrated viral DNA per cell.2

**Engraftment Assay**

Female NOD-Cg-PrkdcscidIl2rgtm1Wjl/Sz (NSG) mice were conditioned with 30 mg/kg busulfan or by irradiation with 270 cGy (cesium source) at day −1 and then transplanted intravenously (i.v.) with 1E6 CD34+ cells. Mice were maintained in sterile conditions and provided with food and water ad libitum. At 4 months post-transplant, bone marrow was processed for genomic DNA, VCN analysis, and integration-site analysis. All protocols were approved by local Institutional Animal Care and Use Committee (IACUC) (bluebird bio, Scripps Research Institute, and Toxicon).

**Flow Cytometry**

Antibodies were purchased from BioLegend and from BD Biosciences. Flow cytometry was performed using an Accuri C6 (BD Biosciences, San Jose, CA, USA), a four-laser SORP BD Fortessa (BD Biosciences), or two-laser SORP BD Aria (BD Biosciences), and analysis was performed using FlowJo software (Tree Star, Ashland, OR, USA).

**Integration-Site Analysis**

We followed the approach of Zhou et al.29 In brief, 1 μg of genomic DNA (gDNA) was sheared using Covaris sonicator, followed by end repair, A-tailing, adaptor ligation, and linear amplification-mediated (LAM) PCR with biotinylated primers. Cleaned up LAM products were further amplified using nested PCR with primers carrying sample-specific bar codes. The libraries were sequenced on Illumina NextSeq in a 150-cycle pair-end run. The reads were trimmed of viral sequences and aligned to hg38 reference genome using bowtie2.30 The positions of mapped reads were further annotated with information about corresponding gene models and features taken from the ENSEMBL genomes database.31

**Statistical Analysis**

Our standard statistical test is a two-sided unpaired t test. Statistical significance is indicated with a p value; N.S. denotes p > 0.05.

**SUPPLEMENTAL INFORMATION**

Supplemental Information includes five figures and one table and can be found with this article online at https://doi.org/10.1016/j.ymthe.2017.09.025.

**AUTHOR CONTRIBUTIONS**

The following authors are or were full-time employees of bluebird bio, Inc. and receive salary and hold equity in bluebird bio, Inc.: G.C.H., M.B., L.C., F.J.P., D.C., Y.S., W.Z., and G.L. The following authors are or were full-time employees of bluebird bio, Inc. and receive salary and hold equity in bluebird bio, Inc.: G.C.H., M.B., L.C., F.J.P., D.C., Y.S., W.Z., A.H., S.S., G.L., K.A.G., H.H., M.H.F., P.D.G., and G.V. The following authors declare no potential conflict of interest: O.G. and B.E.T.

**ACKNOWLEDGMENTS**

The authors thank M. McDonald, I. Shestapolov, and O. Negre for critical review of the manuscript; K. Lewis for editorial assistance; J. Cram, C. Jones, and G. Ford for cell procurement; S. Vemuri and E. Pasackow for technical assistance; A. Thomas, R. Kutner, W. Gormon, and M. Segura and team for LVV production; and B. Ryu, C. Tipper, L. Naldini, L. Zon, J. Grey, E. Yannaki, and G. Stamatoyannopoulos for helpful discussions. This work was funded by bluebird bio, Inc.

**REFERENCES**

1. Böhm, A., Mottini, E., Lorioi, L., Cesani, M., Fumagalli, F., Plati, T., Baldoli, C., Martino, S., Calabrà, A., Canale, S., et al. (2013). Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341, 1233158.
2. Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010). Transfusion independence and HMG2A2 activation after gene therapy of human β-thalassaemia. Nature 467, 318–322.
3. Auriol, A., Biais, L., Scaramuzza, S., Ferrua, F., Cicalèse, M.P., Baricordi, C., Dionisio, F., Calabrà, A., Giannelli, S., Castelli, M.C., et al. (2013). Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 341, 1233151.
4. Scaramuzza, S., Riasco, L., Ripamonti, A., Castello, M.C., Loperfido, M., Draghici, E., Hernandez, R.J., Benedicenti, F., Radrizzani, M., Salomoni, M., et al. (2013). Preclinical safety and efficacy of human CD34(+) cells transduced with lentiviral vector for the treatment of Wiskott-Aldrich syndrome. Mol. Ther. 21, 175–184.

5. Sessa, M., Lorioli, L., Fumagalli, F., Acquati, S., Redaelli, D., Baldoli, C., Canale, S., Lopez, I.D., Morena, F., Calabria, A., et al. (2016). Lentiviral haematopoietic stem cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1/2 trial. Lancet 388, 476–487.

6. Naldini, I. (2015). Gene therapy returns to centre stage. Nature 526, 351–360.

7. Sutton, R.E., Reitsma, M.J., Uchida, N., and Brown, P.O. (1999). Transduction of human progenitor hematopoietic stem cells by human immunodeficiency virus type 1-based vectors is cell cycle dependent. J. Virol. 73, 3649–3660.

8. Shen, H., Cheng, T., Preffer, F.I., Dombkowski, D., Tomasson, M.H., Golan, D.E., Yang, O., Hofmann, W., Soder, J.G., Luster, A.D., and Scadden, D.T. (1999). Intrinsic human immunodeficiency virus type 1 resistance of hematopoietic stem cells despite coreceptor expression. J. Virol. 73, 728–737.

9. Santoni de Sio, F.R., Cascio, P., Zingale, A., Gasparini, M., and Naldini, L. (2006). Proteasome activity restricts lentiviral gene transfer into hematopoietic stem cells and is down-regulated by cytokines that enhance transduction. Blood 107, 4257–4265.

10. Petrillo, C., Cesana, D., Piras, F., Bartolaccini, S., Naldini, L., Montini, E., and Kajaste-Roos, K. (2014). Cyclosporin a and rapamycin relieve distinct lentiviral restriction blocks in hematopoietic stem and progenitor cells. Mol. Ther. 23, 352–362.

11. Wang, C.X., Sather, B.D., Wang, X., Adair, J., Singh, S., Lang, S., Adams, A., Curinga, G., Kiem, H.P., et al. (2014). Rapamycin relieves lentiviral vector transduction resistance in human and mouse hematopoietic stem cells. Blood 124, 913–923.

12. Zhang, J., Scadden, D.T., and Crumpacker, C.S. (2007). Primitive hematopoietic cells resist HIV-1 infection via p21. J. Clin. Invest. 117, 473–481.

13. Li, L., Torres-Coronado, M., Gu, A., Rao, A., Gardiner, A.M., Epps, E.W., Gonzalez, N., Tran, C.A., Wu, X., Wang, J.H., and DiGuisto, D.L. (2014). Enhanced genetic modification of adult growth factor mobilized peripheral blood hematopoietic stem and progenitor cells with rapamycin. Stem Cells Transl. Med. 3, 119–1208.

14. Joglekar, A.V., Stein, L., Ho, M., Hoban, M.D., Hollis, R.P., and Kohn, D.B. (2015). Dissecting the mechanism of histone deacetylase inhibitors to enhance the activity of zinc finger nucleases delivered by integrase-defective lentiviral vectors. Hum. Gene Ther. 25, 599–608.

15. Cavrois, M., De Noronha, C., and Greene, W.C. (2002). A sensitive and specific enzyme-based assay detecting HIV-1 virus fusion in primary T lymphocytes. Nat. Biotechnol. 20, 1151–1154.

16. Goessling, W., North, T.E., Loozer, S., Lord, A.M., Lee, S., Stoick-Cooper, C.L., Wiedinger, G., Puder, M., Daley, G.Q., Moon, R.T., and Zon, L.I. (2009). Genetic interaction of PGE2 and Wntsignaling regulates developmental specification of stem cells and regeneration. Cell 136, 1136–1147.

17. North, T.E., Goessling, W., Walkley, C.R., Loozer, S., Kopani, K.R., Lord, A.M., Weber, C.J., Bowman, T.V., Jang, I.H., Grosser, T., et al. (2007). Prostaglandin E2 regulates vertebrate hematopoietic stem cell homeostasis. Nature 447, 1007–1011.

18. Bhardwaj, G., Murdoch, B., Wu, D., Baker, D.P., Williams, K.P., Chadwick, K., Ling, L.E., Karanu, F.N., and Bhatia, M. (2001). Sonic hedgehog induces the proliferation of primitive human hematopoietic cells via BMP regulation. Nat. Immunol. 2, 172–180.

19. Boitano, A.E., Wang, J., Romeo, R., Bouchez, L.C., Parker, A.E., Sutton, S.E., Walker, J.R., Flavney, C.A., Perdew, G.H., Denison, M.S., et al. (2010). Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 329, 1345–1348.

20. Fares, I., Chagraoui, J., Gareau, Y., Gent, S., Ruel, R., Mayotte, N., Czaizar, E., Knapp, D.J., Miller, P., Ngeon, M., et al. (2014). Cord blood expansion. Pyrimidinolide derivatives are agonists of human hematopoietic stem cell self-renewal. Science 345, 1509–1511.

21. Reya, T. (2003). Regulation of hematopoietic stem cell self-renewal. Recent Prog. Horm. Res. 58, 283–295.

22. Cutler, C., Multani, P., Robbins, D., Kim, H.T., Le, T., Hoggatt, J., Pelus, L.M., Desponta, C., Chen, Y.B., Rezner, B., et al. (2013). Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood 122, 3074–3081.

23. Genovese, P., Scirolli, G., Escobar, G., Tomaso, T.D., Firrito, C., Calabria, A., Moi, D., Mazzieri, R., Bonini, C., Holmes, M.C., et al. (2014). Targeted genome editing in human repopulating hematopoietic stem cells. Nature 510, 235–240.

24. Hayes, M.M., Lane, B.R., King, S.R., Markovitz, D.M., and Coffey, M.J. (2002). Prostaglandin E(2) inhibits replication of HIV-1 in macrophages through activation of protein kinase A. Cell. Immunol. 215, 61–71.

25. Thivierge, M., Le Gouill, C., Tremblay, M.-J., Stankou, J., and Rola-Pleszczynski, M. (1998). Prostaglandin E2 induces resistance to human immunodeficiency virus-1 infection in monocyte-derived macrophages: downregulation of CCR5 expression by cyclic adenosine monophosphate. Blood 92, 40–45.

26. König, R., Zhou, Y., Elleder, D., Diamond, T.L., Bonamy, G.M., Irelan, J.T., Chiang, C.Y., Tu, B.F., De Jesus, P.D., Lilley, C.E., et al. (2008). Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 135, 49–60.

27. Gomez, P.F., Pillinger, M.H., Attur, M., Marjanovic, N., Dave, M., Park, J., Bingham, C.O., 3rd, Al-Mussawir, H., and Abramson, S.B. (2005). Resolution of inflammation: prostaglandin E2 dissociates nuclear trafficking of individual NF-kappaB subunits (p65, p50) in stimulated rheumatoid synovial fibroblasts. J. Immunol. 175, 6924–6930.

28. Malki, S., Nei, S., Notarnicola, C., Thevenet, L., Gasca, S., Mègean, C., Berta, P., Poulant, F., and Boizet-Bonhoure, B. (2005). Prostaglandin D2 induces nuclear import of the sex-determining factor SOX9 via its CAMP-PKA phosphorylation. EMBO J. 24, 1798–1809.

29. Zhou, S., Bonner, M.A., Wang, Y.D., Rapp, S., De Ravin, S.S., Malech, H.L., and Sorrentino, B.P. (2015). Quantitative shearing linear amplification polymerase chain reaction: an improved method for quantifying lentiviral vector insertion sites in transplanted hematopoietic cell systems. Hum. Gene Ther. Methods 26, 4–12.

30. Langmead, B., and Salzberg, S.L. (2012). Fast gapped-read alignment with Bowtie 2. Nat. Methods 9, 357–359.

31. Kersey, P.J., Allen, J.E., Armzen, I., Boddu, S., Bolt, B.J., Carvalho-Silva, D., Christensen, M., Davis, P., Falin, I.J., Grabenhuener, C., et al. (2016). Ensembl Genomes 2016: more genomes, more complexity. Nucleic Acids Res. 44 (D1), D574–D580.